This federal Project Grant award of $495,024.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to examine the impact of psilocybin on brain, cognition, and behavior in individuals with opioid use disorder (OUD). The award will fund a 2-year study across 72 participants that aims to investigate psilocybin's effects on motivational, inhibitory, and cognitive flexibility domains in OUD. Specifically, the research...
This federal Project Grant award of $679,118 from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), supports research at the University of California, Santa Cruz (UCSC) focused on understanding the cellular and circuit-level mechanisms by which the psychedelic compound psilocybin can have long-lasting therapeutic effects in the stressed brain. The key products or services to be delivered through this 5-year grant include: 1)...
This Project Grant award of $131,990 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research into the efficacy of psychedelic drugs, such as DOI and psilocybin, at reversing aberrant reward-seeking behavior associated with depression, addiction, and eating disorders. The research will utilize a well-validated rat model of early-life adversity to examine the effects of these 5-HT2A agonist drugs on food-seeking...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) will support research to investigate the role of cortical GABAergic interneurons in psychedelic drug action. The 5-year, $627,945 grant awarded to Cornell University will examine how psilocybin, a psychedelic compound, affects the activity of the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex. The research aims to provide...
The National Institute on Drug Abuse (NIDA) awarded a 5-year, $1,499,050 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to the Medical College of Wisconsin, Inc. The grant, titled "Investigations into 5-HT2A Signaling Mechanisms of Psychedelic Drugs for the Treatment of Stimulant Use Disorder," will fund research to examine the role of the 5-HT2A receptor signaling pathway in psychedelic drugs' therapeutic potential for treating stimulant use disorders,...
This federal Cooperative Agreement award, with an Assistance Type of Cooperative Agreement, was issued by the National Institute on Drug Abuse (NIDA), which is part of the National Institutes of Health (NIH). The award is funded under CFDA 93.279, the Drug Use and Addiction Research Programs. The award provides $3,244,725.00 to evaluate the use of psilocybin as an adjunctive treatment for opioid use disorder (OUD) in patients maintained on methadone who continue to use illicit opioids. The award...
This federal Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the U.S. Department of Health and Human Services, supports the development of a bioresorbable microdevice that can deliver intermittent sub-perceptual doses of 5HT2A agonists, such as psilocybin, to help mitigate depression associated with opioid use disorder (OUD). The $306,556 award, effective September 15, 2024 through August 31, 2025, aims to produce highly tailored drug...
The federal Project Grant award R01AA031417 for "$708,511.00" was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) federal grant program. The award will fund a randomized controlled trial to investigate the neural mechanisms and therapeutic effects of psilocybin-assisted treatment for alcohol use disorder (AUD). The study aims to evaluate the impact of high-dose psilocybin versus low-dose control on AUD...
The Washington University in St. Louis has been awarded a $130,722 Project Grant by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). This 2-year award, effective July 1, 2024, will fund research to investigate the effects of psychedelic compounds on brain function and neuroplasticity. The project aims to determine how psychedelics like psilocybin and DMT differentially impact neuronal and hemodynamic measures of brain...
This $1,790,186 Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the mechanisms governing stress-immune interactions in people living with HIV (PLWH) and their associated distress and cannabis use disorder (CUD). The research project will use a cross-diagnostic approach to: Determine the hypothalamic-pituitary-adrenal (HPA) and immune response to acute stress among healthy controls, PLWH,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), funded under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting research to investigate a psilocybin-sensitive neuroimmune circuit that may control stress behaviors relevant to substance use disorders (SUDs). The $2,709,842 grant, awarded on May 1, 2024, will be used by Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to define the effects of psilocybin on immune cells in the meninges during chronic stress, determine how psilocybin-sensitive immune cells regulate astrocytes, and evaluate the impact of psilocybin-dependent immune cell effects on reward behavior. This research aims to elucidate how a psilocybin-sensitive neuroimmune circuit may represent a therapeutic target for addressing SUDs influenced by chronic stress.